F32HL082068 (HOLINSTAT, MICHAEL ALLAN)Aug 1, 2005 - Jul 31, 2007 NIH
PAR mediated Rap 1 activation in platelets
Role: Principal Investigator |
|
R00HL089457 (HOLINSTAT, MICHAEL ALLAN)Aug 1, 2007 - Apr 30, 2012 NIH
Thrombin regulation of Rap1 signaling in human platelet activity
Role: Principal Investigator |
|
K99HL089457 (HOLINSTAT, MICHAEL ALLAN)Aug 1, 2007 - Jul 31, 2012 NIH
Thrombin regulation of Rap1 signaling in human platelet activity
Role: Principal Investigator |
|
R01MD007880 (BRAY, PAUL F.)Jul 9, 2013 - Feb 28, 2019 NIH
Genetic regulation of racial differences in platelet reactivity
Role: Co-Principal Investigator |
|
R01HL114405 (HOLINSTAT, MICHAEL ALLAN)Aug 1, 2013 - May 31, 2018 NIH
Role of 12-lipoxygenase in platelet reactivity and type 2 diabetes mellitus
Role: Principal Investigator |
|
R01GM105671 (HOLINSTAT, MICHAEL ALLAN)Aug 1, 2013 - Jul 31, 2019 NIH
12-HETrE regulation of platelets
Role: Principal Investigator |
|
TL1TR002242 (HOLINSTAT, MICHAEL ALLAN)Jun 1, 2017 - Feb 28, 2022 NIH
NRSA Training Core
Role: Principal Investigator |
|
R35GM131835 (HOLINSTAT, MICHAEL ALLAN)Apr 1, 2019 - Mar 31, 2025 NIH
12-HETrE regulation of blood coagulation, hemostasis, and thrombosis
Role: Principal Investigator |
|
R21TR003185 (HOLINSTAT, MICHAEL ALLAN)Jun 11, 2021 - May 31, 2024 NIH
Biomarkers for 12-lipoxygenase inhibition as a therapeutic intervention for heparin-induced thrombocytopenia and thrombosis (HIT/T)
Role: Principal Investigator |
|
T32TR004371 (HOLINSTAT, MICHAEL ALLAN)Apr 1, 2023 - Mar 31, 2028 NIH
CTSA Predoctoral T32 at the University of Michigan
Role: Principal Investigator |
|
R01HL181954 (ABDEL LATIF, AHMED)Aug 1, 2026 - Apr 30, 2030 NIH
Macrophage 12-Lipoxygenase Signaling as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction
Role: Co-Principal Investigator |